PDF
Targeting mutated KRAS in the first-line therapy
Hideaki Ijichi
| [1] |
Zhu C, Guan X, Zhang X, et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022;21:159.
|
| [2] |
Drosten M, Guerra C, Barbacid M. Genetically engineered mouse models of K-Ras-driven lung and pancreatic tumors: validation of therapeutic targets. Cold Spring Har Perspect Med. 2018;8:a031542.
|
| [3] |
Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371-2381.
|
| [4] |
Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med. 2022;387:120-131.
|
| [5] |
Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRASG12C inhibition in cancer. N Engl J Med. 2021;384:2382-2393.
|
| [6] |
Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N Eng J Med. 2023;389:2125-2139.
|
| [7] |
Kuboki Y, Fakih M, Strickler J, et al. Sotorasib with panitumumabu in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024;30:265-270.
|
| [8] |
Desai J, Alonso G, Kim SH, et al. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nat Med. 2024;30:271-278.
|
| [9] |
Kemp SB, Cheng N, Markosyan N, et al. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov. 2023;13:298-311.
|
/
| 〈 |
|
〉 |
AI Summary
